Description: TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Home Page: www.tetralogicpharma.com
343 Phoenixville Pike
Malvern,
PA
19355
United States
Phone:
610 889 9900
Officers
| Name | Title |
|---|---|
| Dr. Yigong Shi Ph.D. | Co-Founder |
| Sarah E. Frew | Director of Bus. & Commercial Devel. |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4016 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2013-12-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 29 |